AffiliationCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractThe bryostatins are a group of novel macrocyclic lactones derived from the marine bryozoan, Bugula neritina. In vitro evidence indicates that their main mechanism of action is modulation of protein kinase C (PKC) activity. Phase I studies suggested significant antineoplastic activity against several tumor types and defined the main dose-limiting toxicity as myalgia. Bryostatin-1 has subsequently been investigated extensively in phase II clinical trials as a single agent, although trial design has been hampered by lack of human pharmacokinetic data. Results have been generally disappointing but in vitro and animal data suggests an important role for bryostatin-1 in combination with cytotoxic agents. Preliminary results of phase I studies support these observations but further work needs to be done to define the future role of the bryostatins in the clinic.
CitationThe clinical development of the bryostatins. 2002, 13 (7):673-83 Anticancer Drugs
- Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.
- Authors: Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, Al-Katib AM
- Issue date: 2001
- A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
- Authors: Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy RL, Smith DL, Bernstein M
- Issue date: 1999 Sep
- Bryostatin-1: a novel PKC inhibitor in clinical development.
- Authors: Kortmansky J, Schwartz GK
- Issue date: 2003
- Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
- Authors: Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F
- Issue date: 1993 Nov 17
- A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
- Authors: Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S
- Issue date: 1995 Aug